ROCKAWAY, NJ , Oct. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper entitled “Non-invasive vagus nerve stimulation for treatment of cluster headache: a retrospective review of
Health Canada expands gammaCore label to include the acute and preventive treatment of migraine in adolescents ROCKAWAY, NJ , Oct. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that the company received an amended
Third q uarter 2021 revenue expected to be approximately $1.5 million Net cash used to fund operations in the third quarter 2021 of approximately $3.5 million ROCKAWAY, NJ , Oct. 12, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today
ROCKAWAY, NJ , Oct. 07, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced the granting of the company’s motion to dismiss the federal court securities class action case filed in Trenton, NJ .
ROCKAWAY, NJ , Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference has been rescheduled to today, September 30,
ROCKAWAY, NJ , Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-1 study; a prospective, randomized, controlled study evaluating non-invasive vagus nerve
ROCKAWAY, NJ , Sept. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference . The
ROCKAWAY, NJ , Sept. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Board of Directors has appointed Peter Cuneo as Chairman of the Board of Directors effective October 1, 2021 . Mr.
ROCKAWAY, NJ , Sept. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methods
ROCKAWAY, NJ , Sept. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received Section 510(k) clearance from the United States Food and Drug Administration (FDA) of the